Valeant Pharmaceuticals International Inc. will sell Sprout Pharmaceuticals to former Sprout shareholders, the company said Monday, after they accused the struggling pharmaceutical giant of botching the marketing of a female libido treatment. Valeant purchased Sprout and its only drug, Addyi, two years ago for about $1 billion. Sales of the drug haven’t provided close to a return on the investment, and this year RBC Capital Markets forecasted the drug will ring up less than $10 million in sales.

Source: Wall Street Journal November 06, 2017 13:44 UTC